FDA approves GSK’s Hibsago as first functional cure for hepatitis B - Pharmaceutical Technology

GSK's likely blockbuster-to-be led to a fifth of patients having undetectable viral levels in clinical trials. GSK's likely blockbuster-to-be led to a fifth of patients having undetectable viral levels in clinical trials. The approval marks a significant moment for US patients with the chronic form of the liver disease. Credit: testing/Shutterstock.com. The US Food and Drug Administration (FDA) has approved GSK’s Hibsago (bepirovirsen), marking the first functional cure available to hepatitis B patients in the US. The drug will be available for patients without cirrhosis, already receiving nucleos(t)ide analogue reverse transcriptase inhibitor (NRTI) therapy for at least six months who…

Source: Pharmaceutical Technology